FundingHealthcare & Life Sciences
Biodimension raises ₹8 crore from IAN Angel Fund
By Abha Lohia · Editor ·
Biodimension: funding and every story →
Bengaluru
- Biodimension makes lab-grown human tissue and organ models that replace animal testing
- It raised ₹8 crore in a round led by IAN Angel Fund, with Campus Angels Network and angel investors
- The company plans to expand its cancer biobank and scale its on-demand testing service
What happened
- Biodimension raised ₹8 crore in a funding round led by IAN Angel Fund.
- Existing investor Campus Angels Network also participated in the round.
- Angel investors Dr. Sampath Srisailam and Aaryan Baid joined the round.
- The company will use the funds to accelerate product development and expand laboratory infrastructure.
- It will also strengthen its scientific and commercial teams to drive commercialization in India and abroad.
- Biodimension plans to expand its Pan-Cancer Tumour Microenvironment Biobank and add new oncology models.
- It aims to scale its Bioassay-as-a-Service platform and expand into Southeast Asia, Europe, the US, and Japan.
Why it matters
- India imports most of its human tissue testing models even though it is a large pharma manufacturing hub.
- Biodimension's locally made models meet global regulatory standards and are cheaper and quicker for Indian researchers to obtain.
- This funding supports the company's effort to offer homegrown alternatives to imported testing products.
The business
- Biodimension creates lab-grown human tissue and organ models that serve as ethical substitutes for animal testing.
- Its customers include pharmaceutical, biotech, and cosmetic research companies.
- Key products are BioDEpi (a reconstructed human skin layer for safety tests), BioDFT (a full-thickness skin model), and BioDPigma (a pigmented skin model).
- It also runs a Pan-Cancer Tumour Microenvironment Biobank for cancer drug research.
- The company offers a Bioassay-as-a-Service (BaaS) platform that performs on-demand human-relevant tests.
- Biodimension works with pharma companies, biotech firms, research institutes, and contract research organizations in India and Singapore.
- Its headquarters are in Bengaluru, India.
The founders
MS
Manojkumar S.
Co-Founder and CEORK
Ranjith Kumar Velusamy
Co-FounderPA
Pradeep Arunachalam
Co-FounderWho put in money
- IAN Angel Fund lead — Evergreen fund of IAN Group, an Indian angel investor network.
- Campus Angels Network participated — Existing investor in Biodimension.
- Dr. Sampath Srisailam participated — Angel investor.
- Aaryan Baid participated — Angel investor.
In numbers
₹8 croreFunding raised · 2026
What happens next
- Accelerate product development and expand laboratory infrastructure.
- Strengthen scientific and commercial teams.
- Drive commercialization in India and international markets.
- Expand Pan-Cancer Tumour Microenvironment Biobank and add new oncology and immunotherapy models.
- Scale Bioassay-as-a-Service platform.
- Expand across Southeast Asia and build partnerships in Europe, the US, and Japan.
Words to know
- biofabricated human tissue
- Laboratory-grown human tissue that mimics real human biology, used for testing instead of animal models.
- organoid
- A miniature, simplified version of an organ grown in a lab from stem cells, used for research and drug testing.
- Pan-Cancer Tumour Microenvironment Biobank
- A collection of preserved samples from various cancers that include the surrounding cells and structures, used to study how tumours interact with their environment.
- Bioassay-as-a-Service (BaaS)
- A service where a company performs biological tests on demand for clients, using human-relevant models instead of animals.
The numbers around it
Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →
Other articles talking about it
Terms in this story
- Angel investor: An angel investor is a wealthy individual who puts personal money into a very young startup, often before it has steady revenue, in return for shares. In India most angels write cheques from a few lakh to a few crore rupees, and as of November 2026 pooled angel funds may take money only from accredited investors.
- Angel network: An angel network is a group of individual investors who find, screen and fund startups together. A syndicate is a smaller version: one lead angel brings a deal and others follow, usually through one vehicle. In India, a network pooling member money into an angel fund must register with SEBI and, as of November 2026, accept only accredited investors.
- Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.
- Angel syndicate: An angel syndicate is a group of investors that back one startup together, led by an experienced angel who finds the deal, negotiates it and speaks for the group. In India it usually runs through an SEBI-registered angel fund or a pooled vehicle, so the startup sees one investor on its cap table instead of dozens.
Read next
NewsBiodimension builds human tissue alternatives to animal testingBiodimension makes reconstructed human tissues and organoids for drug discovery and cosmetics testingFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Biodimension → · All startup news on 11 June 2026 →
Is this Biodimension? Get your “Featured on StopDown” badge →